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Abstract
Purpose Nail damage is common amongst patients receiving chemotherapy causing disfigurement and pain. This investiga-
tion evaluated whether a topical balm containing steam-extracted, bioactive polyphenolic-rich herbal oils blended with organic 
waxes could protect the nails via their reported anti-inflammatory, analgesic, anti-oxidant and anti-microbial properties.
Methods 60 patients (23M, 37F) were randomised to apply (2–3/day) either the plant balm (PB) or a petroleum control (PC) 
to their nail beds. Demographics, type and number of chemotherapy cycles did not differ between the two groups, recruited 
between Sept 2015 and Sept 2016. An unpaired t test was used to test the differences in symptoms and physical nail damage 
between the two groups.
Results Symptom scores recorded with the dermatology life quality questionnaire (DLQQ) were significantly better, between 
the start and end of chemotherapy, in the group applying the PB versus PC. Likewise, the mean fall in nail damage, scored 
with the Nail Psoriasis Index by the supervising physician, was also significantly different.
Conclusion The polyphenolic-rich essential oils and plant-based waxes in this nail bed balm profoundly reduced chemo-
therapy-related nail damage and improved nail-related quality of life, compared to a control. A further analysis is planned 
combining this balm with nail bed cooling.
Keywords Prevention of onycholysis · Breast cancer · Prostate cancer · Taxane chemotherapy side effect · Quality of life · 
Randomised · Double-blind clinical trial
Discussion and implications for clinical 
practice
Scientific evidence for practical strategies to reduce this dis-
tressing and unsightly side effect of one of the most com-
monly used chemotherapy drugs is long overdue. Up until 
now, many patient advocacy groups have advised patients to 
use dark nail varnish or standard petroleum-based nail balms 
to an attempt to help protect their nails during chemotherapy, 
but there is little published evidence for their effectiveness 
or even anecdotal reports of helping [1]. Cooling the nails 
during chemotherapy has been shown to reduce nail tox-
icity but commercially available gloves are rarely used in 
the UK, as nurses have practical concerns about restricted 
access to patients’ hands. The profoundly lower levels of 
physical nail damage and improvements in nail-related qual-
ity of life in the cohort applying the plant-based balm in 
this robustly designed RCT strongly suggest that this balm 
will benefit future patients receiving chemotherapy in route 
clinical practice. As nail toxicity still occurred in a minor-
ity of participants, who had marked general side effects of 
chemotherapy, further research combining this balm with 
cooling would be justified.
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Introduction
Chemotherapy-induced onycholysis is caused by disorgan-
ised inhibition of the rapidly dividing cells in the nail bed 
[2–5]. Further contributory factors relate to the anti-angio-
genetic properties of taxanes and excess local inflammatory 
mediated processes [2–5]. Disruption of the normal anatomy 
allows bacterial and fungal pathogens to enter the nail beds 
causing further damage [2, 5]. In most cases this manifests 
as ridges in the nails that correspond to the timings of chem-
otherapy episodes, known as Beau’s lines (Image 1). More 
pronounced nail damage, particularly associated with taxa-
nes, can lead to discolouration, painful subungual haemor-
rhages (Image 2), distortion and complete onycholysis which 
is distressing, unsightly, affects body image (Images 3, 4), 
limits activities of daily living and may lead to more seri-
ous consequences including secondary infection which is a 
particular concern amongst patients at risk of neutropenia 
[2–6].
Cooling the fingers has been reported to reduce doc-
etaxel-related nail toxicity by initiating vasoconstriction and 
slowing the metabolism of onychocytes [7–9]. This tech-
nique, however, has not been commonly adopted in the UK, 
as oncology nurses have concerns about restricting access 
to patients’ hands. Patient support groups advise a variety 
of anecdotal strategies including wearing nail varnish and 
massaging moisturising petroleum-based balms into the nail 
bed, but there have been no robust prospective studies to 
support these practices [1].
The plant-based waxes and essential oils selected for 
this study are naturally rich in phytochemicals, especially 
the phenolic polyphenols group which are reported to have 
anti-oxidant, anti-inflammatory, DNA repair enhancing and 
anti-microbial properties [10–17]. In addition to their abili-
ties to moisturise the skin, preventing drying and the split-
ting of nails, it was hypothesised, they would be sufficiently 
absorbed into the nail beds to act as a local antidote to the 
chemotherapy, preventing damage to the proliferating stem 
Image 1  Mild, asymptomatic nail changes corresponding to the 
cycles of chemotherapy—Beau’s Lines
Image 2  Uncomfortable, chemotherapy induced subungual haemor-
rhages
Image 3  Painful chemotherapy induced parial onycholyis
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cells as well as avoiding secondary damage from inflamma-
tion or secondary infection [10–19].
Methodology
The study recruited for 13 months at one of Cambridge Uni-
versity’s affiliated hospitals, Bedford Hospital. In total, 23 
men with prostate cancer and 37 women with breast cancer 
receiving chemotherapy were randomised from a total of 63 
patients considered for this study, between September 2015 
and October 2016. One patient declined entry after reading 
the information materials and two had pre-existing nail con-
ditions [See consort diagram]. Following written informed 
consent, randomisation occurred when the supervising phy-
sician contacted the trials office who then opened the next 
sealed envelope in strict numerical order. The randomised 
groups were demographically equally matched in terms of 
number of chemotherapy cycles received, gender, chemo-
therapy type, baseline nail health and age (see Table 1). The 
balms were supplied in 50 ml pots, labelled A or B, together 
with an applicator. They were similar in colour, consistency 
and smell. Participants were shown how to apply their allo-
cated balm to their finger nail beds, 2–3 times a day, until 
the end of their chemotherapy (Images 5, 6). No members of 
the research team, physicians, participants or the statistician 
were aware of the contents of either balm pot until the final 
results were analysed.
Image 4  Severe, distressing subungual haemorrhages and secondary 
infection leading to complete onycholysis
Table 1  Demographics
Plant balm Placebo Statistical difference
Number for analysis 30 30 0 (ns)
Average age 57.2 66.3 9.1 (NS)
Sex (women:men) 18:11 19:12 1 (ns)
Average chemo cycles 4.4 5.2 0.8 (ns)
Received taxotere 28 29 1 (ns)
Image 5  Polybalm applied to cuticles, surrounding skin and nail beds 
on the fingers preserving nail health
Image 6  Polybalm applied to cuticles of toe nails
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At baseline and at the end of chemotherapy, patients 
recorded symptoms relating to their nail health using the 
validated Dermatology Life Quality Questionnaire plus a 
Linear Severity Scale (LSS). Physicians recorded the physi-
cal appearance of the nails using the validated Nail Psoriasis 
Severity Index (NPSI) plus the Linear Severity Scale. Photo-
graphs of the nails were also sent to further three independ-
ent physicians for external validation.
Ingredients of the balms
The PB consisted of a blend of unrefined shea butter 
(Butyrospermum parkii), organic beeswax (Cera alba), 
extra virgin, organic, cold-pressed olive oil (Olea europaea), 
organic cocoa seed butter (Theobroma cacao), African sage 
Assessed for eligibility (n=63)
Excluded  (n= 3)
♦ Not meeting inclusion criteria (n= 1) 
♦ Declined to participate (n=1 ) 
♦ Psoriasis onycholysis (n= 1) 
Analysed  (n= 30)
♦ Excluded from analysis (n= 0)
Lost to follow-up (give reasons) (n= 0)
Discontinued intervention (n= 0) 
Allocated to interventional balm (n= 30)
♦ Received allocated intervention (n= 0)
♦ Did not receive intervention (n=0 )
Lost to follow-up (give reasons) (n= 0)
Discontinued intervention (n= 0) 
Allocated to petroleum balm control (n= 30)
♦ Received allocated intervention (n= 0)
♦ Did not receive intervention (n=0 )
Analysed  (n=30)
♦ Excluded from analysis (n=0)
Allocation 1:1
Analysis
Follow-Up
Randomized (n= 60)
(Tarchonanthus camphoratus), wintergreen leaf (Gaulthe-
ria procumbens), lavender flower (Lavandula spica) and 
eucalyptus leaf (Eucalyptus globulus). The oils were steam 
extracted from the plants and then gently blended, avoiding 
overheating to prevent damage to the phytochemicals. They 
contained no preservatives, parabens, sulphates or perfumes. 
The placebo control balm contained hydrogenated petroleum 
oil, candela wax, lavender and eucalyptus essences to ensure 
their placebo effect.
Quality assurance
The trial was designed with the help of the independent 
National Cancer Research Clinical Trials Development 
Committee as well as oncologists from Addenbrooke’s Hos-
pital, advisors from the Department of Biological Science 
Table 2  Summary of average 
chance in score at baseline and 
end of study
Nail health record Plant Balm Placebo Difference (CI) Power
Dermatology life quality questionnaire − 0.034 − 6.10 6.06 CI 4.17–7.95 p < 0.00001
Linear severity scale (mm) +2.63 − 64.1 66.72 CI 52.97–80.47 p < 0.00001
Nail Psoriasis Index (NPSI) 0.0 − 5.71 5.71 CI 4.29–7.12 p < 0.00001
Linear analogue scale (mm) − 5.79 − 66.1 60.30 CI 45.29–75.32 p < 0.00001
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at Coventry University and an independent statistician. 
The study was externally audited to comply with Good 
Clinical Practice (GCP) guidelines, and East of England—
Cambridge Central Research Ethics Committee standards 
(REC reference: 15/EE/0357). The investigational balms 
were made specifically for this study by Power Health Ltd, 
Yorkshire. Additional stability and microbial tests of the 
formula were performed by Advantis Laboratories Ltd, to 
comply with European Union Cosmetics Standards (REC 
Ref: 76/768/EEC).
Statistical considerations
The sample size was determined considering a previously 
reported incidence of chemotherapy-induced onycholysis 
of between 40 and 70% [2–5]. The trial development com-
mittee deemed that deterioration in nail toxicity score of 
20% was clinically significant. For the power calculation, 
the nearest relevant trial using similar toxicity grading scores 
evaluated the benefits of a frozen glove on the incidence of 
onycholysis which had 20 and 25 patients, respectively, to 
produce an 80% statistical power for a two-sided test at the 
α = 0.05 level. A Matlab 2011a calculation was employed 
to determine the sample size. The resultant graph estimated 
that 50 patients would have been adequate to detect a 20% 
difference in toxicity with a √2*standard deviation (SD) 
of confidence of using a two-sided test at the α = 0.05 level. 
The trial committee therefore decided on 60 participants to 
allow unforeseen events or dropouts. The analysis compared 
the difference in nail damage scores between the start of the 
study and end of chemotherapy, and between the plant balm 
and control groups, using an unpaired t test for all four meas-
ures of nail health with a significance level of α = 0.05 at 
95%.
Results
Patient and physician measures of nail toxicities demon-
strated large and statistically significant differences between 
the plant balm (PB) and placebo control (PC) groups 
(Table 2). In the PB group, the DLQQ score dropped from 
baseline to the end of the chemotherapy by an average of 
0.034. In the PC group, the DLQQ score dropped by an aver-
age of 6.10. This resulted in a mean difference in the level 
of deterioration of quality of life of 6.06, confidence inter-
vals (CI) 4.17–7.95, a significance of p < 0.00001 using an 
unpaired t test. For the linear severity scale (LSS) the aver-
age condition of the nails recorded by the patients actually 
improved over the course of chemotherapy by 2.63 mm 
in the PB cohort compared to a deterioration of 64.1 mm 
in the PC group (difference 66.72 mm; CI 52.97–80.47, 
p < 0.00001). Difference in the physical appearances of the 
nails was similarly large and statistically significant meas-
ured using the validated NAPSI as well as a Standard Linear 
Analogue Scale. The figures for the other measures of nail 
health are summarised in Table 2.
It was interesting to note that the two patients in the plant 
balm group who still had moderate damage, also suffered 
from other severe chemotherapy complications including 
neutropenic sepsis, diarrhoea and peripheral neuropathy. 
There were no reported balm-related adverse toxicities 
although one patient in the plant balm group discontinued 
use before the end of the first cycle, quoting time constraints 
as the reason for stopping.
Discussion
The phytochemical-rich essential oils and plant-based waxes 
in this nail bed balm considerably reduced the physical 
appearance and distress of chemotherapy-induced nail dam-
age compared to a petroleum-based control balm. In terms 
of trial design, it may have seemed more relevant to have 
considered a within patient comparison, applying one cream 
to one hand and the other to the opposite hand. However, this 
was dismissed as impractical by the design committee, as 
breaches in compliance would have overridden any statisti-
cal benefits as participants would very likely have mixed 
up the allocated hands and as soon as any difference were 
realised. The second design issue was the choice of placebo 
control. As there were no published nail bed balm data avail-
able at the start of the trial, a statistically valid comparison 
would be an investigational balm versus no balm. This, how-
ever, would have meant that the trial would not have been 
blind; so a simple, commonly used, petroleum-based balm 
was chosen, with added essences determined by the manu-
facturers. It was assumed that the control may have provided 
some benefit via its moisturising properties, but not have the 
potential additional properties of the plant oils and waxes.
Previous studies have reported that regular oral intake of 
polyphenol-rich foods and supplements has demonstrated 
skin protection from sun damage, and lower the risk of 
chronic inflammatory diseases including arthritis, diabe-
tes and cancer as well as improved recovery after exercise 
[20–23]. The potential benefits of topical phytochemical-
rich plant extracts have been explored in laboratory studies, 
but only in a limited number of clinical trials despite their 
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popular inclusion in skincare cosmetics [15, 24]. They have 
not previously been investigated in the onycholysis setting. 
This study did not elucidate which of the reported bioactive 
pathways of these phytochemicals provided the most benefit, 
but there are several potential possibilities.
Their anti-oxidative properties could have potentially pro-
tected the rapidly proliferating onychocytes from oxidative 
damage [12, 13, 15–17]. Gaultheria procumbens, particu-
larly high in methyl-salicylate, may have reduced an inflam-
mation reaction against the nail bed tissues initiated by local 
chemotherapy damage, preventing further structural damage. 
These properties may have reduced discomfort via their local 
analgesic properties [11, 14, 25]. Tarchonanthus camphora-
tus, containing phenolic acids, flavonoids and tannins, has 
also been shown to have anti-inflammatory properties with 
potency twice as high as that of indomethacin. In addition, 
its bactericidal and fungicidal properties could have pro-
tected the nail bed from secondary infection, especially if 
splits or cracks had occurred [25, 26]. Both Lavandula offici-
nalis and Eucalyptus globulus contain lactones, flavonoids, 
tannins, phenolic acids and terpene esters, which also have 
anti-inflammatory, anti-fungal and bacteriocidal properties 
[25, 26]. The base waxes create a protective barrier for skin 
which helps it to retain moisture, preventing splitting and 
cracking of the nail bed which could allow entry of patho-
gens [24, 26]. Unlike the standard petroleum-based waxes, 
they also have bioactive properties of their own.
Olea europaea, predominantly oleic acid, has anti-oxidant 
and anti-inflammatory properties [24] and has demonstrated, 
in a randomised laboratory study, to reduce epidermal levels 
of 8-hydroxy-deoxyguanosine, a marker for DNA damage 
after animals were exposed to excess sunlight [15]. Theo-
broma cacao and Butyrospermum parkii, approved by the 
FDA for use as natural bases in cosmetics, have anti-oxidant 
properties via their vitamin E and A content, and even after 
processing, cera alba has anti-bacterial and anti-fungal prop-
erties [24, 26]. Although there are some overlaps in these 
properties, by including different plant extracts, each with 
a range of phytochemicals, it was hypothesised that their 
different reported modes of action would have a synergistic 
protective affect [24–26].
In conclusion, the large difference between the control 
and interventional balms in this double-blind randomised 
study strongly suggests that the phytochemicals in natural 
oils and waxes were sufficiently absorbed into the nail beds 
to enable their bioactive properties to protect participants 
from the harmful effects of chemotherapy. In this study, 
participants applied the balm at the start, or near the start 
of chemotherapy, so the study did not answer the research 
question of whether this balm could prevent further deterio-
ration, or provide relief once damage had occurred. Precisely 
which properties and of which ingredient had the most rel-
evant benefit, was not answered in this study, and further 
research in this field is certainly justified, as this could lead 
to enhanced versions of this and other topical therapies. Fur-
ther research, combining different versions of balm with or 
without nail cooling, is planned to evaluate whether this will 
further protect patients from the distress of onycholysis.
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Appendix: A double blind, randomised 
evaluation of nail bed balms to prevent 
chemotherapy‑induced onycholysis—The 
polybalm study
Patient Initials:___  ___ Trial No.:___  ___ Date:___/___/___
Please indicate treatment cycle:
Baseline C2 C3 C4 C5 C6 C7 C8 C9 C10
Over the last seven days, please circle the response which you feel best answers the questions about your
fingernails.
Not at all A little bit Somewhat
Quite a 
bit
Very 
much
1 I have pain in my fingernails. 0 1 2 3 4
2 I have redness and swelling around my fingernails and the nail bed. 0 1 2 3 4
3 The condition of my nails limits my daily activities. 0 1 2 3 4
4 I am upset by the appearance of my nails. 0 1 2 3 4
Please hand this questionnaire back to a member of the research team. Thank you.
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